ATE482979T1 - Ups als den beta-catenin-pfad modifizierende substanzen und anwendungsverfahren - Google Patents

Ups als den beta-catenin-pfad modifizierende substanzen und anwendungsverfahren

Info

Publication number
ATE482979T1
ATE482979T1 AT04781084T AT04781084T ATE482979T1 AT E482979 T1 ATE482979 T1 AT E482979T1 AT 04781084 T AT04781084 T AT 04781084T AT 04781084 T AT04781084 T AT 04781084T AT E482979 T1 ATE482979 T1 AT E482979T1
Authority
AT
Austria
Prior art keywords
methods
beta
ups
application
catenin pathway
Prior art date
Application number
AT04781084T
Other languages
English (en)
Inventor
Helen Francis-Lang
Christopher Winter
Richard Ventura
Timothy Heuer
Kim Lickteig
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of ATE482979T1 publication Critical patent/ATE482979T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04781084T 2003-08-14 2004-08-12 Ups als den beta-catenin-pfad modifizierende substanzen und anwendungsverfahren ATE482979T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49517203P 2003-08-14 2003-08-14
PCT/US2004/026339 WO2005017119A2 (en) 2003-08-14 2004-08-12 Ups as modifiers of the beta catenin pathway and methods of use

Publications (1)

Publication Number Publication Date
ATE482979T1 true ATE482979T1 (de) 2010-10-15

Family

ID=34193286

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04781084T ATE482979T1 (de) 2003-08-14 2004-08-12 Ups als den beta-catenin-pfad modifizierende substanzen und anwendungsverfahren
AT04781103T ATE469175T1 (de) 2003-08-14 2004-08-13 Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04781103T ATE469175T1 (de) 2003-08-14 2004-08-13 Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren

Country Status (8)

Country Link
US (2) US20080050313A1 (de)
EP (3) EP1651674B1 (de)
JP (3) JP2007502119A (de)
AT (2) ATE482979T1 (de)
AU (3) AU2004265661A1 (de)
CA (3) CA2535901A1 (de)
DE (2) DE602004029368D1 (de)
WO (3) WO2005017118A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4606712B2 (ja) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
JP2010515434A (ja) 2007-01-05 2010-05-13 マサチューセッツ インスティテュート オブ テクノロジー Ｆｌａｖｏｂａｃｔｅｒｉｕｍｈｅｐａｒｉｎｕｍ由来のスルファターゼを使用する組成物および方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4670388A (en) 1982-12-30 1987-06-02 Carnegie Institution Of Washington Method of incorporating DNA into genome of drosophila
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
WO1998042876A1 (en) 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6066500A (en) * 1999-06-25 2000-05-23 Isis Pharmaceuticals Inc. Antisense modulation of Beta catenin expression
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
WO2001060985A2 (en) * 2000-02-14 2001-08-23 Yale University Compositions, methods and kits relating to uridine phosphorylase gene mutations
EP1358349A2 (de) * 2000-06-05 2003-11-05 Avalon Pharmaceuticals Bestimmung von krebsgenen und therapeutisches screeningverfahren das signaturen von gensätzen verwendet
US20020015943A1 (en) * 2000-07-31 2002-02-07 Mariann Bienz Assays, methods and means relating to the modulation of levels of nuclear beta-catenin
EP1958642A1 (de) 2000-12-22 2008-08-20 Dana-Farber Cancer Institute Regulierung des Zellwachstums durch MUC1
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
JP2005504533A (ja) * 2001-09-06 2005-02-17 ザ ジェネラル ホスピタル コーポレーション プロテインキナーゼＣλと関連のある疾患および状態の診断および治療のための方法
WO2003052068A2 (en) * 2001-12-13 2003-06-26 Exelixis, Inc. Mbcats as modifiers of the beta-catenin pathway and methods of use
US20040014049A1 (en) * 2002-07-19 2004-01-22 Isis Pharmaceuticals Inc. Antisense modulation of protein kinase C-iota expression

Also Published As

Publication number Publication date
US20070128606A1 (en) 2007-06-07
WO2005017118A3 (en) 2006-07-06
ATE469175T1 (de) 2010-06-15
EP1651674A4 (de) 2006-09-20
AU2004264952B2 (en) 2010-12-16
JP2007502118A (ja) 2007-02-08
EP1654349A4 (de) 2008-08-20
AU2004265662B2 (en) 2010-12-16
DE602004027387D1 (de) 2010-07-08
WO2005017119A2 (en) 2005-02-24
WO2005016282A2 (en) 2005-02-24
AU2004264952A1 (en) 2005-02-24
EP1653915B1 (de) 2010-05-26
WO2005016282A3 (en) 2006-04-06
DE602004029368D1 (de) 2010-11-11
JP2007502119A (ja) 2007-02-08
JP2007515935A (ja) 2007-06-21
CA2535901A1 (en) 2005-02-24
EP1654349A2 (de) 2006-05-10
EP1653915A4 (de) 2007-09-05
EP1653915A2 (de) 2006-05-10
CA2535812A1 (en) 2005-02-24
EP1651674B1 (de) 2010-09-29
AU2004265662A1 (en) 2005-02-24
US20080050313A1 (en) 2008-02-28
AU2004265661A1 (en) 2005-02-24
EP1651674A2 (de) 2006-05-03
WO2005017119A3 (en) 2006-01-26
CA2535897A1 (en) 2005-02-24
WO2005017118A2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
ATE483976T1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
WO2005016279A3 (en) Melks as modifiers of the rac pathway and methods of use
ATE482979T1 (de) Ups als den beta-catenin-pfad modifizierende substanzen und anwendungsverfahren
DE602006018461D1 (de) Galk1s als modifikatoren des pten/akt-wegs
ATE536549T1 (de) Galnts als modifikatoren des igfr-weges und verwendungsverfahren
DE602005025737D1 (de) C20orf23 als modifikator des igfr-wegs und verwendungsverfahren
WO2005017121A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2005072475A3 (en) Itpks as modifiers of the igfr pathway and methods of use
WO2004048537A3 (en) Lamps as modifiers of the p53 pathway and methods of use
WO2005052131A3 (en) C140rf35 as modifier of the beta catenin pathway and methods of use
WO2004005483A3 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
DE602006021421D1 (de) Ngsverfahren
WO2004015072A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2005003305A3 (en) Usps as modifiers of the beta catenin pathway and methods of use
WO2004067721A3 (en) Tkts as modifiers of the beta-catenin pathway and methods of use
WO2004104168A3 (en) Mrbs as modifiers of the rb pathway and methods of use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties